Edwards Lifesciences Corp (EW) CEO Michael A. Mussallem Sells 32,800 Shares

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $178.99, for a total value of $5,870,872.00. Following the completion of the transaction, the chief executive officer now owns 84,601 shares in the company, valued at approximately $15,142,732.99. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of NYSE EW opened at $178.89 on Wednesday. The company has a market capitalization of $37.76 billion, a P/E ratio of 38.06, a PEG ratio of 2.32 and a beta of 0.85. Edwards Lifesciences Corp has a 52 week low of $134.38 and a 52 week high of $197.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.66 and a quick ratio of 2.69.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.23 by $0.09. The business had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.22 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corp will post 5.28 earnings per share for the current year.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a report on Thursday, May 9th. Deutsche Bank upped their target price on Edwards Lifesciences from $164.00 to $184.00 and gave the company a “hold” rating in a report on Wednesday, April 24th. Jefferies Financial Group upped their target price on Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. BMO Capital Markets upped their target price on Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Finally, BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a report on Wednesday, April 24th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $187.00.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FTB Advisors Inc. bought a new stake in Edwards Lifesciences during the first quarter worth approximately $25,000. Executive Wealth Management LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $25,000. Sontag Advisory LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $26,000. Field & Main Bank bought a new stake in Edwards Lifesciences during the first quarter worth approximately $34,000. Finally, Lindbrook Capital LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $27,000. 84.62% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2019/05/15/edwards-lifesciences-corp-ew-ceo-michael-a-mussallem-sells-32800-shares-2.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: How to Invest in a Bull Market

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.